Curiva’s Solution
Curiva is dedicated to transforming the way cervical cancer is diagnosed. Their premiere solution, the diaPatch™, is a non-invasive diagnostic patch that offers same-visit results with higher accuracy. In development by world-class experts, this innovative product leverages microneedles and a novel assay to detect cervical cancer biomarkers with high sensitivity and specificity.
The diaPatch™ provides several distinct advantages over traditional Pap smears and colposcopies. The patch is non-invasive, utilizing microneedles to extract liquid biopsy samples, making the procedure painless and anxiety-free. It also has a higher sensitivity, significantly reducing the likelihood of false negatives compared to the 55.4% sensitivity of Pap smears. The diaPatch™ provides faster results and achieves a higher accuracy, ensuring fewer false positives compared to Pap smears.
Additionally, the diaPatch™ seamlessly integrates into modern healthcare practices. It streamlines workflows for providers and enhances patient compliance through its companion app, the ELLEApp™. This app provides results to both the provider and the patient, offers reminders to support patient compliance, integrates with electronic health records (EHRs), and facilitates follow-ups or referrals.
For more information about Curiva, visit www.curiva.co and follow them on LinkedIn
For more information on Femovate visit www.Femovate.com and follow us on LinkedIn
For interviews, please contact Theresa Neil
